GENEART is the solution provider for DNA engineering and processing in the field of improved medicine and biotechnology.
As the world wide leading supplier for synthetic genes, we deliver services to academia and industry, which comprise:

 




Your advantages:

  • system solutions in DNA engineering and processing for improved drugs and biotech products 
  • outstanding service quality
    (certified by external audits and according to ISO 9001:2000)
  • highest production capacity in industry 
  • highest security levels for confidential customer data 
  • proprietary optimization and production process 

GENEART is listed on Frankfurt stock exchange, ISIN: DE000A0JJ4L4 and thus the first publicly listed gene synthesis company world wide. This access to the capital market reflects our binding commitment to market and technology leadership.